Low risk of hemolysis after transfusion of uncrossmatched red blood cells by Radkay, Lisa et al.
IMMUnoHeMAtoLoGY, Volume 28, number 2, 2012 39
Low risk of hemolysis after transfusion of 
uncrossmatched red blood cells
L. Radkay, D.J. Triulzi, and M.H. Yazer
Transfusing uncrossmatched red blood cells (RBCs) can be a life-
saving bridge until crossmatched RBCs are available. The risk of 
using uncrossmatched RBCs is that of hemolysis from unexpected 
clinically significant antibodies. This study sought to quantify 
the risk of hemolysis after the transfusion of uncrossmatched 
RBCs. The records of recipients of uncrossmatched RBCs over 
approximately 9 months were retrieved from the regional trans-
fusion service. Basic immunohematologic data were recorded 
on all recipients including the number of uncrossmatched RBCs 
transfused. For recipients who had either previously identified 
clinically significant antibodies or those identified on the day 
of transfusion, clinical and biochemical data were evaluated to 
determine whether hemolysis had occurred after uncrossmatched 
RBC transfusion. There were 218 recipients of 1065 units of 
uncrossmatched RBCs. Most of the RBCs were administered 
in the emergency room (48%) followed by the operating room 
(24%) and intensive care unit (23%). Seven (3.2%) recipients had 
clinically significant antibodies that were active on the day of 
the transfusion, whereas in four patients a clinically significant 
antibody had been previously identified but was not active on the 
day of the transfusion. One patient with active antibodies who 
received three units of uncrossmatched RBCs for a gastrointestinal 
bleed demonstrated a reactive eluate several days later as well as 
positive biochemical hemolysis markers. Thus the overall rate of 
detectable hemolysis after uncrossmatched RBC transfusion was 
1 of 218 (0.5%). The use of uncrossmatched RBCs is a relatively 
safe intervention, although close monitoring of recipients with 
clinically significant antibodies for evidence of hemolysis is 
recommended. Immunohematology 2012;28:39–44.
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Under uncomplicated circumstances, crossmatched 
red blood cells (RBCs) can usually be available within 
approximately 60 minutes of the patient’s blood sample 
arriving at the blood bank. However, there are circumstances 
under which this short delay in providing RBCs can be life 
threatening to the recipient. In these cases, uncrossmatched 
RBCs, which are RBC units whose compatibility with the 
recipient’s plasma has not been serologically or electronically 
verified, can be provided almost immediately for use during an 
acute resuscitation while the blood bank performs a forward 
and reverse type and an antibody screen. As uncrossmatched 
RBCs are always group O, immediate hemolysis caused 
by naturally occurring anti-A and anti-B is avoided. The 
main risk of using uncrossmatched RBCs is the potential 
for hemolysis caused by unexpected non-ABO antibodies; 
thus the risk of hemolysis after receiving uncrossmatched 
RBCs is directly related to whether the recipient has either 
received a previous transfusion or been pregnant. In a 
situation in which uncrossmatched RBCs might be used, 
such as in trauma resuscitation in the emergency department, 
the patient’s pregnancy and transfusion history are often 
unknown; however, the risk of immediate hemolysis caused 
by unexpected clinically significant antibodies should be low 
because the prevalence of these antibodies in the general 
population is quite low. In a study of almost 16,000 patients 
(corresponding to nearly 28,000 antibody screens) at a tertiary 
care hospital in Australia, only 1.9 percent of the recipients 
had a positive screen caused by a clinically significant 
antibody, of which the majority were directed toward antigens 
in the Rh or Kell systems.1 When stratified by age, women 
generally had a higher incidence of alloimmunization than 
men, and patients with hematologic or oncologic diseases had 
higher rates of alloimmunization compared with patients in 
the emergency room or trauma patients. Similarly, Heddle 
and colleagues demonstrated that 96.5 percent of previously 
transfused patients at their hospital had a negative antibody 
screen,2 whereas Stack et al. demonstrated a 2.4 percent 
alloimmunization rate among 18,750 transfused veterans.3
Several previous studies have evaluated patient outcomes 
after receipt of uncrossmatched RBCs.4–11 In general, the risk 
of hemolysis was either low or absent, but it was not always 
clear whether the recipients in these studies had active 
antibodies on the day that they received their uncrossmatched 
RBC transfusion, thereby putting them at risk of hemolysis. 
A detailed study of 265 uncrossmatched RBC transfusion 
episodes by Goodell and colleagues found that 6.4 percent 
of these incidents were complicated by the presence of a 
clinically significant antibody.4 However, only one of seven 
of the recipients with a clinically significant antibody who 
received at least one incompatible uncrossmatched RBC 
unit actually had a hemolytic reaction. Thus, we sought to 
determine the incidence of hemolysis after the administration 
of uncrossmatched RBCs throughout our hospital system.
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Materials and Methods
The records of patients who were at least 16 years of 
age and received at least one uncrossmatched RBC unit 
over an approximately 9-month period were retrieved from 
the electronic records of a regional transfusion service. This 
transfusion service covers 16 hospitals in southwestern 
Pennsylvania including several level 1 trauma centers, 
active solid organ and stem cell transplantation services, 
and a variety of intensive care units. From the transfusion 
service’s electronic files, basic serologic information on each 
recipient was recorded; this included the previous detection 
of alloantibodies, whether antibodies were detected on the 
day of receipt of the uncrossmatched RBCs, the detection 
of new antibodies after receipt of uncrossmatched RBCs, 
and the number of uncrossmatched RBC units transfused. 
Reports of transfusion reactions temporally associated with 
the uncrossmatched RBC transfusions were also recorded. 
Clinically significant antibodies were defined as those 
capable of causing hemolysis or shortening the lifespan 
of the transfused RBCs, and for which antigen-negative, 
crossmatch-compatible RBC units should be transfused.12 
Basic demographic data from the clinical records of the 
patients who received uncrossmatched RBCs were noted. 
For patients who had either known historical or active 
clinically significant antibodies on the day that they received 
uncrossmatched RBCs, biochemical variables including 
bilirubin, haptoglobin, lactate dehydrogenase, reticulocyte 
counts, and hemoglobin levels as well as the results of direct 
antiglobulin tests (DATs) and eluates were also analyzed, if 
available, to determine whether immune-mediated hemolysis 
had occurred at any point after the uncrossmatched RBC 
transfusion. The patient’s clinical chart was also reviewed to 
determine whether there was a clinical suspicion of hemolysis. 
These laboratory and clinical variables were also analyzed 
in those recipients who subsequently produced antibodies 
after receipt of uncrossmatched RBCs. The physician and 
nursing notes from around the time of the uncrossmatched 
transfusions were also examined to determine whether there 
was a clinical suspicion of hemolysis.
Antibody detection was performed using a manual 
saline tube technique (Immucor, Norcross, GA) or automated 
techniques including column agglutination (Ortho ProVue; 
Ortho Clinical Diagnostics, Rochester, NY) and solid-
phase (Galileo; Immucor) methodologies according to 
the manufacturer’s specifications. The polyspecific and 
monospecific DATs (Ortho, Raritan, NJ) and eluates (Gamma 
Elu-kit II; Immucor) were performed using commercially 
available reagents and kits. As per our reference laboratory 
protocols, an eluate would have been performed on a specimen 
that demonstrated a newly positive DAT or one that had 
increased in strength from a previous test in a patient with 
a recent transfusion history, or if specifically ordered by a 
physician. Most of the uncrossmatched RBCs would not have 
been leukoreduced and would be stored in AS-3 or AS-5 
solutions. The decision to use uncrossmatched RBCs was made 
by the patient’s clinical team, and uncrossmatched RBCs were 
available from the blood bank and from remote monitored 
refrigerators in the emergency room and on selected wards. 
The prescribing physician was required to have signed and 
returned to the blood bank an authorization form for the use of 
uncrossmatched RBCs.
Descriptive statistics were used for continuous variables 
using the software package in Microsoft Excel 2010. Results 
are presented as mean ± standard deviation. This protocol 
was approved by the University of Pittsburgh’s Total Quality 
Council.
Results
During the approximately 9-month period, there were 
218 recipients of at least one unit of uncrossmatched RBCs. 
The mean age of these recipients was 54 ± 21 years, and 65 
percent were male. Overall, 1065 uncrossmatched RBC units 
were transfused to these 218 recipients, which represents an 
average of 4.9 ± 4.9 uncrossmatched RBC units per recipient. 
Most of the uncrossmatched RBCs were administered in the 
emergency room (48%), followed by the operating room (24%), 
and the intensive care unit (23%). The remaining units were 
administered on medical floors, in labor and delivery suites, 
in the interventional radiology department, and to one patient 
who was receiving extracorporeal membrane oxygenation. 
Transfusion reactions were reported in two recipients of 
uncrossmatched RBCs who did not have known historical 
or active antibodies, and as expected, neither reaction was 
hemolytic in nature; one patient had hypotension in the 
operating room, the etiology of which was believed to be 
related to the patient’s underlying hypovolemia from dialysis 
and ongoing bleeding. The signs and symptoms of the other 
reaction were not specific in nature, and it was reported in a 
patient who received the uncrossmatched RBCs during her 
unsuccessful resuscitation for hemorrhage.
Figure 1 presents the immunohematologic outcomes after 
receipt of the uncrossmatched RBCs. Of the 218 recipients 
of uncrossmatched RBCs, seven had active antibodies 
on the day of transfusion, and four others had historical 
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clinically significant antibodies that were not active on the 
day of the transfusion. Table 1 presents the demographic 
and immunohematologic details of the 11 patients who had 
historical or active clinically significant antibodies when 
they received their uncrossmatched RBC units. In one of four 
recipients with historical clinically significant antibodies no 
further antibody screens were performed after receipt of the 
uncrossmatched RBCs; in another recipient only K– selected 
antibody screening cells were used for antibody detection, 
so it was not possible to determine whether the historical 
anti-K had reappeared. In the remaining two patients, their 
historical anti-Jka and -K had not reappeared in antibody 
screens performed 14 and 100 days, respectively, after receipt 
of uncrossmatched RBCs.
Overall, only one recipient demonstrated biochemical or 
clinical evidence of immune-mediated hemolysis after receipt 
of uncrossmatched RBCs. The patient (Patient 4 in Table 1) was 
a 72-year-old man who received three units of uncrossmatched 
RBCs as a result of gastrointestinal bleeding. The antibody 
screen performed on a pretransfusion sample revealed anti-K, 
-Fya, -E, and -Cw, which had been detected previously. On this 
sample the anti-IgG DAT was 2+ with a nonreactive eluate. 
Because of the patient’s condition, uncrossmatched RBCs had 
to be issued before the pretransfusion evaluation could be 
completed. A sample drawn 3 days later revealed a 2+ anti-IgG 
DAT with a weak positive anti-C3d, and on this sample the 
eluate revealed both anti-E and -Fya (the eluate was performed 
because of the clinical suspicion of hemolysis). The patient’s 
hemoglobin before the uncrossmatched RBC transfusion was 
7.2 g/dL (normal, 12.3–15.5 g/dL) and increased to 10.8 g/
dL on the following day. His hemoglobin gradually decreased 
over the next 2 days to a nadir of 8.2 g/dL without further 
evidence of bleeding. The patient’s creatinine was 1.9 mg/dL 
(normal, 0.5–1.17 mg/dL) before the uncrossmatched RBC 
transfusion and then increased to 2.4 mg/dL the day after 
receipt of uncrossmatched RBCs, at which time hemodialysis 
was instituted. The total bilirubin was only measured 6 days 
after the transfusion and was 16.1 mg/dL (normal, 0.1–1.2 
mg/dL). The other biochemical markers of hemolysis such as 
reticulocyte count, lactate dehydrogenase, haptoglobin, or urine 
Fig. 1 Flow diagram demonstrating the immunohematologic consequences of receiving uncrossmatched RBCs. *The numbers do not add to 
218 because 2 patients are counted in multiple categories: both patients had active clinically significant antibodies along with an insignificant 
antibody on the day of receipt of the uncrossmatched RBCs.
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hemoglobin were not ordered on this patient. The patient died 
within 1 week of the uncrossmatched RBC transfusion. The 
reactive eluate in the setting of a decline in hemoglobin after 
uncrossmatched RBC transfusion, the increased bilirubin, and 
the worsening renal function are highly suggestive of immune-
mediated hemolysis caused by the transfusion of incompatible 
uncrossmatched RBC units.
Several patients had clinically insignificant antibodies. 
There were two patients who had cold autoantibodies detected 
on the day of the uncrossmatched RBC transfusion, whereas 
a patient with four active clinically significant antibodies also 
had a history of a cold autoantibody that was not reacting on 
the day of the RBC transfusion (Patient 4 in Table 1). Two other 
patients had histories of anti-A1 and warm autoantibodies, 
respectively, and another patient had a warm autoantibody 
along with anti-E that were both active on the day of the 
transfusion (Patient 7 in Table 1).
In total, four patients developed antibodies after 
receipt of uncrossmatched RBCs. Two patients developed 
antibodies within a short time after the uncrossmatched RBC 
transfusion; a 27-year-old D– male patient received two units 
of uncrossmatched D+ RBCs, and anti-D was detectable on 
an antibody screen 10 days later. This patient had a negative 
antibody screen 5 days after the RBC transfusion, and did not 
receive additional D+ RBC units between the uncrossmatched 
units and the detection of anti-D. A 30-year-old man developed 
anti-E 16 days after receipt of 18 uncrossmatched RBC units. 
His last negative antibody screen was 13 days after the 
uncrossmatched RBC transfusions, and the only addtitional 
RBCs he received were one crossmatched unit 5 days before 
the anti-E was detected, suggesting that the stimulus for the 
production of the antibody was the uncrossmatched RBCs 
themselves. Neither of these patients had a history of RBC 
transfusion or historical antibodies in the electronic records of 
the regional transfusion service; furthermore, neither patient 
demonstrated biochemical or clinical evidence of hemolysis 
after detection of the antibody. In the remaining two patients, 
the antibodies were detected on screens that were more 
remote from the time of the uncrossmatched RBC transfusion 
compared with the two patients described above; a 19-year-old 
male patient with no previous transfusion or antibody history 
on file at the transfusion service developed anti-Jka 30 days 
after the uncrossmatched RBCs. He had a negative antibody 
screen 4 days after the uncrossmatched RBC transfusion, and 
the anti-Jka was subsequently detected on his next screen. He 
received multiple crossmatched RBCs in the interval between 
the uncrossmatched RBCs and the detection of the anti-Jka. 
Similarly, a 59-year-old woman with a history of anti-K 
developed anti-D and anti-E 62 and 72 days, respectively, 
after the uncrossmatched RBC transfusion (Patient 6 in Table 
1). This patient had five negative antibody screens before the 
anti-D and -E were detected, and the last negative screen 
was 47 days after the uncrossmatched RBC transfusion. 
She continued to receive multiple D+ RBCs in between the 
uncrossmatched RBCs and the detection of anti-D. As with 
the two patients described earlier, neither of these patients 
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Table 1. Demographic and immunohematologic characteristics of the patients with clinically significant historical or active antibodies at the 
















identified on the 










1 74 F ICU 6 N D, K Y N
2 67 F ICU 2 N S, Kpa Y N
3 53 M OR 6 N Jka Y N
4 72 M ICU 3 N K, Fya, E, Cw Y Y
5 28 F OR 8 N K, Fya Y N
6 59 F ED 2 N K Y N
7 81 M ED 2 N E Y N
8 29 F OR 5 N D N N
9 78 F ICU 2 N S Y N
10 89 F ED 2 N c Y N
11 62 M ICU 2 N K N N
ED = emergency department; ICU = intensive care unit; OR = operating room.
*As documented in the electronic records of this regional transfusion service.
Antibodies in bold reflect those that were active on the day of the uncrossmatched RBC transfusion.
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had biochemical or clinical evidence of hemolysis after the 
uncrossmatched RBC transfusion.
Discussion
In our cohort, only 11 of 218 (5%) of the patients who 
received uncrossmatched RBCs had either a history of a 
clinically significant antibody or one that was active on the 
day of the transfusion. It is important to consider not only 
the patients with clinically significant antibodies that were 
active on the day of the RBC transfusion but also the patients 
with a history of a clinically significant antibody because 
evanescence is complicated and it is difficult to predict when 
or whether it will occur for a given antibody. Furthermore, 
recent data suggest that previously acquired antibodies seem 
to evanesce at a lower rate than newly formed antibodies.13 
Thus, antibodies that had been detected previously might 
still be present at a titer on the day of the uncrossmatched 
RBC transfusion sufficient to cause the immune-mediated 
hemolysis of incompatible units. Using the data from the 
current study, the risk of hemolysis after uncrossmatched RBC 
transfusion can be viewed in several ways. If only the patients 
with clinically significant antibodies that were active on the 
day of the uncrossmatched RBC transfusion are considered, 
then the risk is 1 of 7 (14%). Considering patients with either 
historical or active clinically significant antibodies, then the risk 
is 1 of 11 (9%). However, as frequently no immunohematologic 
information on a bleeding patient is available at the time the 
decision is made to use uncrossmatched RBCs, perhaps the 
most clinically relevant rate of hemolysis is 1 of 218 (0.5%), 
with the denominator including all of the patients in this study. 
These figures are similar to those from the study by Goodell 
et al. in which of the 265 uncrossmatched RBC transfusion 
episodes, 17 of the recipients had clinically significant 
antibodies and 1 patient had at least an exacerbation of an 
underlying immune-mediated hemolytic reaction.4 Thus the 
evidence from the current study and that from the previous 
studies suggests that the use of uncrossmatched RBCs in the 
setting of a life-threatening hemorrhage is a relatively safe 
bridge until crossmatched RBCs become available.
As crossmatched RBCs are typically only matched for ABO 
and D, the use of uncrossmatched RBCs should not result in a 
higher incidence of anamnestic antibody responses or delayed 
hemolytic reactions compared with use of crossmatched RBCs. 
This is particularly true when the recipient’s transfusion history 
is unknown or if there is no documentation of a historical 
antibody. That “new” antibodies in this study were detected 
relatively quickly after the uncrossmatched transfusions in 
two recipients without a history of antibodies suggests that 
these antibodies were possibly the product of a secondary 
immune response to D and E, respectively. Although the 
appearance of the anti-D could have been avoided had D– 
RBCs been transfused to the 27-year-old male recipient, O– 
RBC inventory pressures on the day of the uncrossmatched 
RBC transfusion required the use of D+ RBCs. Given that he 
did not receive other D+ blood products before the anti-D was 
detected, there is little doubt that the uncrossmatched RBCs 
were the stimuli for the reappearance of the anti-D. In the 
absence of any immunohematologic history, the sensitization 
to E in the other male recipient could not have been avoided by 
routine clinical practice. It is unclear whether the antibodies in 
the two other patients were stimulated by the uncrossmatched 
RBCs or by the additional RBCs that these patients received 
before their respective antibodies were detected.
The main limitation of this study is that we were not able 
to determine whether the patients with clinically significant 
antibodies on the day of the uncrossmatched RBC transfusion 
actually received RBCs that were incompatible with their 
antibody. Thus the observed rates of hemolysis in this study 
might be artificially low if the uncrossmatched RBCs were 
lacking the cognate antigen(s). In fact only D– uncrossmatched 
RBCs were transfused to two of the patients with active anti-D, 
although one of those recipients also had an active anti-K on 
the day she received uncrossmatched RBCs. Likewise, it is 
also possible that the recipient with the historical anti-Jka 
who had an antibody screen performed 14 days after receipt 
of the uncrossmatched RBCs was not reexposed to the cognate 
antigen; hence, the antibody did not reappear. Another 
limitation of the study is that because of the retrospective 
nature, the recipients were not specifically monitored for 
hemolysis after the transfusion of uncrossmatched RBCs; 
had each recipient of uncrossmatched RBCs been carefully 
followed after his or her transfusion with serial measurements 
of the biochemical markers of hemolysis and antibody screens, 
then perhaps evidence of hemolysis would have been detected 
in more patients. Furthermore, one patient who received 
uncrossmatched RBCs during resuscitation for septic shock 
died within a few hours of the transfusion; although no mention 
of an acute hemolytic event was made in the clinical notes of the 
resuscitation, a more thorough assessment was not possible; 
hence, the current rate of hemolysis might be slightly higher 
than reported. With the exception of the four recipients who 
produced an antibody after receipt of uncrossmatched RBCs, 
the number and results of subsequent antibody screens among 
the patients who did not have a known active or historical 
antibody on the day that they received their uncrossmatched 
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RBC transfusions were not recorded; thus we cannot derive the 
rate at which delayed serologic or hemolytic reactions occurred 
after the transfusion of uncrossmatched RBCs. This rate is not 
expected to be higher among recipients of uncrossmatched 
RBCs compared with recipients of crossmatched RBCs in our 
system because we do not routinely provide extended antigen-
matched RBCs to most recipients.
Although hemolysis after the transfusion of 
uncrossmatched RBCs is an uncommon event that occurred 
in less than 1 percent of all recipients of uncrossmatched 
RBCs, close clinical and laboratory monitoring of recipients 
for evidence of hemolysis is warranted if a history of or active 
clinically significant antibodies are discovered on subsequent 
serologic investigation.
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